Zinecard, Savene(dexrazoxane)
Savene, Totect, Zinecard (dexrazoxane) is a small molecule pharmaceutical. Dexrazoxane was first approved as Zinecard on 1995-05-26. It is used to treat breast neoplasms in the USA. It has been approved in Europe to treat extravasation of diagnostic and therapeutic materials.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| dexrazoxane | ANDA | 2023-01-24 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| breast neoplasms | EFO_0003869 | D001943 | C50 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J1190 | Injection, dexrazoxane hydrochloride, per 250 mg |
Clinical
Clinical Trials
49 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sarcoma | D012509 | 1 | 6 | 2 | — | 1 | 10 | ||
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 5 | 1 | 3 | — | — | 8 | |
| Cardiotoxicity | D066126 | EFO_1001482 | 1 | 1 | 5 | — | — | 7 | |
| Myeloid leukemia acute | D015470 | C92.0 | 2 | 2 | 1 | — | — | 5 | |
| Neuroblastoma | D009447 | EFO_0000621 | 1 | 2 | 1 | — | — | 4 | |
| Lymphoma | D008223 | C85.9 | — | — | 3 | — | — | 3 | |
| Ganglioneuroblastoma | D018305 | — | 1 | 1 | — | — | 2 | ||
| Leukemia | D007938 | C95 | — | — | 2 | — | — | 2 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | 1 | — | — | 2 |
| Primitive neuroectodermal tumors peripheral | D018241 | — | — | 1 | — | — | 1 |
Show 3 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ewing sarcoma | D012512 | EFO_0000173 | — | 3 | — | — | — | 3 | |
| Myelodysplastic syndromes | D009190 | D46 | 1 | 1 | — | — | — | 2 | |
| Rhabdomyosarcoma | D012208 | — | 2 | — | — | — | 2 | ||
| Philadelphia chromosome | D010677 | — | 1 | — | — | — | 1 | ||
| Myeloid sarcoma | D023981 | C92.3 | — | 1 | — | — | — | 1 | |
| Antineoplastic combined chemotherapy protocols | D000971 | — | 1 | — | — | — | 1 | ||
| Leiomyosarcoma | D007890 | — | 1 | — | — | — | 1 | ||
| Fibrosarcoma | D005354 | — | 1 | — | — | — | 1 | ||
| Liposarcoma | D008080 | — | 1 | — | — | — | 1 | ||
| Hemangiosarcoma | D006394 | — | 1 | — | — | — | 1 |
Show 3 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 3 | — | — | — | — | 3 | |
| Large-cell lymphoma anaplastic | D017728 | C84.6 | 2 | — | — | — | — | 2 | |
| Osteosarcoma | D012516 | 1 | — | — | — | 1 | 2 | ||
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | 2 | — | — | — | — | 2 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | 1 | — | — | — | — | 1 | ||
| Non-hodgkin lymphoma | D008228 | C85.9 | 1 | — | — | — | — | 1 | |
| Extranodal nk-t-cell lymphoma | D054391 | C86.0 | 1 | — | — | — | — | 1 | |
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | 1 | — | — | — | — | 1 | |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | 1 | — | — | — | — | 1 |
Show 6 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vomiting | D014839 | HP_0002013 | R11.1 | — | — | — | — | 1 | 1 |
| Nausea | D009325 | HP_0002018 | R11.0 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DEXRAZOXANE |
| INN | dexrazoxane |
| Description | (+)-dexrazoxane is a razoxane. It has a role as a chelator, an antineoplastic agent, a cardiovascular drug and an immunosuppressive agent. |
| Classification | Small molecule |
| Drug class | alpha-adrenoceptor antagonists (benzodioxane derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 |
Identifiers
| PDB | — |
| CAS-ID | 24584-09-6 |
| RxCUI | 42736 |
| ChEMBL ID | CHEMBL1738 |
| ChEBI ID | 50223 |
| PubChem CID | 71384 |
| DrugBank | DB00380 |
| UNII ID | 048L81261F (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Totect - Cumberland Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,109 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,197 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more